Medroxyprogesterone acetate tablets

Pharmacological action Medroxyprogesterone acetate is an oral synthetic steroid drug derived from progesterone. Except for the presence of a methyl group at position 6 and an acetyloxy group at position 17, this product has the same structure as natural progesterone. Medroxyprogesterone acetate has progestogen-like effects as well as anti-estrogen and anti-gonadotropin effects. At a certain dose, medroxyprogesterone acetate can exert effects on the endocrine system and at the cellular level at the same time. Toxicological studies show that the LD50 of oral medroxyprogesterone acetate is greater than 10g/kg in mice. The subcutaneous LD50 of mice and rats is greater than 10g/kg, and that of guinea pigs is greater than 3g/kg. The tolerated dose of a single injection in dogs is 0.4g/kg. There is no obvious toxic reaction in the above-mentioned animals. Toxicological studies of repeated oral administration in rats and monkeys and repeated intramuscular injection in rats, rabbits and dogs have shown that the main target organs of oral medroxyprogesterone acetate are the reproductive organs and adrenal glands of female and male animals. In addition, mild (oral) or mild to severe (intramuscular) liver toxicity has also been found. Mild hematologic toxicity (oral) and local reactions due to accumulation of unabsorbed material (IM) have been observed. Medroxyprogesterone acetate affects reproductive organs in animals; parenteral administration has been teratogenic in rabbits. No data are available on the perinatal and postpartum use of medroxyprogesterone acetate in animals. Like other progestins, medroxyprogesterone acetate is carcinogenic in dogs; however, the uncertainty regarding the relevance of this finding to humans has been confirmed by large-scale clinical trials.

The main ingredient of this product is: medroxyprogesterone acetate. Chemical name: 6α-methyl-17α-hydroxypregnane-4-ene-3,20-dione acetate

This product is white round tablets.

This product is used to treat the following diseases: breast cancer, endometrial cancer, prostate cancer, kidney cancer, and prostate adenoma.

Oral administration. This product must be taken under the guidance of an experienced doctor. Breast cancer: 0.5-1.5g per day is recommended, or even up to 2g per day (large doses can be divided into 2-3 doses per day). Hormone-dependent tumors such as endometrial cancer, prostate cancer, and kidney cancer: 0.1-0.5g per day. Generally, 0.1g at a time, three times a day; or 0.5g orally once a day.

Medroxyprogesterone acetate has the following side effects like other progestins: breast tenderness, galactorrhea, vaginal bleeding, menstrual changes, amenorrhea, edema, weight changes, changes in the degree of cervical erosion or cervical secretions, jaundice, rash with or without itching, and depression.

It is contraindicated for patients who are allergic to medroxyprogesterone acetate; patients with thrombophlebitis, thromboembolic diseases, severe liver dysfunction, miscarriage, hypercalcemia that may occur in patients with bone metastases, and unexplained uterine bleeding; it is contraindicated for pregnant women.

Precautions for children: Use with caution Precautions for pregnancy and lactation: Contraindicated for pregnant women Precautions for the elderly: Not yet clear.

Progesterone inhibits the metabolism of cyclosporine, resulting in increased plasma concentrations of cyclosporine. Rifampicin accelerates the metabolism of progesterone, resulting in reduced efficacy. Progesterone can significantly reduce the bioavailability of aminoglutethimide.

Keep away from light and store in sealed container.

2 mg

24 months.